Core Viewpoint - Grocery Outlet Holding Corp. is facing a securities fraud lawsuit due to alleged misrepresentations regarding its financial performance and operational growth, particularly related to excessive store expansion that lacked a sustainable profitability path [2][5]. Group 1: Financial Impact - Grocery Outlet shares experienced a significant decline of $2.45 per share, representing a 27.9% drop, closing at $6.34 on March 5, 2026, following corrective disclosures [2]. - The lawsuit claims that the company reported financial and operational growth that was artificially inflated by aggressive store openings, including 22 new stores in the first half and 13 in the third quarter of fiscal 2025 [4]. - The company disclosed the closure of 36 underperforming stores and $110 million in long-lived asset impairment charges, alongside missed guidance across adjusted EBITDA, net sales, comparable store sales, and diluted adjusted earnings per share [2][4]. Group 2: Legal Proceedings - Institutional investors holding positions in Grocery Outlet during the class period from August 5, 2025, to March 4, 2026, may seek to lead the class action, with a lead plaintiff deadline set for May 15, 2026 [1][5]. - The action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5, alleging that the company's management made materially false and misleading statements regarding its financial performance and growth sustainability [3][5]. - Institutional lead plaintiffs historically achieve larger recoveries per share compared to cases led by individual investors, emphasizing the importance of institutional participation in the litigation process [3][4].

Core Viewpoint - A securities class action lawsuit has been filed against Camping World Holdings, Inc. due to alleged misrepresentation of financial controls by executives, leading to significant stock price declines [1][2]. Group 1: Lawsuit Details - The class action lawsuit is pending in the United States District Court for the Northern District of Illinois, covering the period from April 29, 2025, to February 24, 2026 [1][2]. - CWH shares experienced a decline of 24.8% on October 29, 2025, and an additional 16.5% on February 25, 2026, following disclosures of deteriorating margins and inventory mismanagement [2]. Group 2: Individual Defendants - Three senior officers are named as individual defendants, who allegedly controlled the company's public disclosures during the class period [3]. - The individual defendants include Marcus A. Lemonis (CEO), Matthew D. Wagner (President), and Thomas E. Kirn (CFO), each responsible for various aspects of the company's financial reporting and public statements [5]. Group 3: Sarbanes-Oxley Act Implications - Under the Sarbanes-Oxley Act, the CEO and CFO certified that the company's reports accurately represented its financial condition, despite claims that internal controls were inadequate [4]. - The lawsuit alleges that these certifications were misleading, as the company reported a net loss of $109.1 million in Q4 2025 and paused its quarterly dividend [6]. Group 4: Control Person Framework - Section 20(a) of the Securities Exchange Act of 1934 holds individuals liable if they act as "controlling persons" of a company that violates securities laws [6]. - The complaint asserts that the individual defendants were aware of adverse facts that were not disclosed to the public while making positive representations about the company's financial health [10].

IT Investor Alert: Gartner, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Minimized Slowdown Risks: Levi & KorsinskyMar 24, 2026 4:00 PM Eastern Daylight TimeIT Investor Alert: Gartner, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Minimized Slowdown Risks: Levi & KorsinskyShareTime-Sensitive: Allegations Focus on Macroeconomic and Tariff Risk RepresentationsNEW YORK--(BU ...

Core Viewpoint - AQUESTIVE THERAPEUTICS, INC. is facing a securities fraud lawsuit, with claims that CEO Daniel Barber misrepresented the company's prospects, leading to significant investor losses [1][2]. Group 1: Lawsuit Details - The class action lawsuit involves a class period from June 16, 2025, to January 8, 2026, during which AQST shares experienced a significant decline [1][2]. - On January 9, 2026, AQST shares fell by $2.30, representing a decline of over 37% in a single day [2]. - The court has set a deadline of May 4, 2026, for investors to apply for lead plaintiff appointment in the class action [2]. Group 2: Allegations Against CEO - Daniel Barber, as CEO, is accused of having control over the company's SEC filings and public communications, which allegedly contained misleading information regarding the Anaphylm NDA regulatory timeline [2][3]. - The lawsuit claims that Barber failed to disclose material information about deficiencies in the Anaphylm NDA, despite certifying the accuracy of the company's SEC filings [3][7]. - Under the Sarbanes-Oxley Act, Barber had personal liability for the accuracy of the company's public disclosures, which are now under scrutiny due to alleged omissions [3][7]. Group 3: Legal Framework - The lawsuit invokes Section 20(a) of the Securities Exchange Act of 1934, which holds controlling persons liable for violations of federal securities laws [3][4]. - Corporate officers, including CEOs, have a duty to ensure the accuracy and completeness of public statements, and the lawsuit seeks to hold Barber accountable for alleged misrepresentations [4].

Group 1 - A class action lawsuit has been announced by Rosen Law Firm on behalf of Coty Inc. shareholders who purchased common stock between November 5, 2025, and February 4, 2026 [1] - Investors who purchased Coty common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Coty made false and misleading statements regarding its performance in the beauty market, particularly highlighting underperformance in the Consumer Beauty market and compressed margins due to increased marketing investments [5] Group 2 - Interested investors can join the Coty class action by visiting the provided link or contacting Rosen Law Firm for more information [3][6] - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4] - No class has been certified yet, meaning investors are not represented by counsel unless they choose to retain one [7]

Core Viewpoint - Investors in Trip.com Group Limited (TCOM) who have incurred significant losses have the opportunity to lead a securities fraud class action lawsuit against the company [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that between April 30, 2024, and January 13, 2026, the defendants failed to disclose the regulatory risks associated with Trip.com's monopolistic business practices [3]. - It is claimed that the defendants made materially misleading positive statements regarding the company's business, operations, and prospects, which lacked a reasonable basis [3]. Group 2: Participation Information - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith before May 11, 2026, to participate in the ongoing lawsuit [2][4]. - Individuals do not need to take any immediate action to be part of the class action and may choose to retain counsel or remain absent [5].

Core Viewpoint - Rosen Law Firm is reminding investors of Plug Power Inc. about the opportunity to lead a securities fraud lawsuit due to significant losses incurred during the specified class period [1][5]. Group 1: Lawsuit Details - The class period for the lawsuit is defined as January 17, 2025, to November 13, 2025, during which investors may have experienced losses exceeding $100,000 [1]. - The lawsuit alleges that Plug Power made false and misleading statements regarding the availability of funds from the U.S. Department of Energy and the company's ability to construct necessary hydrogen production facilities [5]. - It is claimed that these misrepresentations led to a pivot towards less commercially viable projects, resulting in damages to investors when the truth was revealed [5]. Group 2: Participation Information - Investors wishing to join the class action can do so without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To serve as a lead plaintiff, interested parties must file a motion with the court by April 3, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Achieve Life Sciences, Inc. due to significant losses following the company's financial disclosures [1][3][4]. Group 1: Investigation Details - The investigation focuses on whether Achieve Life Sciences' executive officers complied with federal securities laws after the company reported continued operating losses and limited cash reserves [3][4]. - Following the financial results announcement on March 24, 2026, Achieve Life Sciences' stock price experienced a significant decline during intraday trading [3]. Group 2: Company Background - Achieve Life Sciences reported its fourth quarter and full-year 2025 financial results, highlighting ongoing operational challenges [3]. - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, representing both individual and institutional investors [5]. Group 3: Firm Achievements - In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms, recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel [6].

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health during its IPO, leading to significant stock price declines after the announcement of increased expenses [1][3][4]. Group 1: Class Action Lawsuit Details - Investors who purchased Navan's common stock during its October 31, 2025 IPO have until April 24, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1]. - The lawsuit, titled McCown v. Navan, Inc., claims violations of the Securities Act of 1933 by Navan and its executives [1][2]. - Navan's IPO involved the issuance of nearly 37 million shares at an offering price of $25.00 per share [2]. Group 2: Financial Allegations - The lawsuit alleges that Navan's offering documents were materially misleading, omitting the fact that the company would increase its sales and marketing expenses by 39% shortly after the IPO [3]. - On December 15, 2025, Navan reported a 39% increase in sales and marketing expenses to nearly $95 million, up from $68.5 million in the previous quarter [4]. - Following the announcement of increased expenses, Navan's stock price fell nearly 12% [4]. Group 3: Stock Performance - By the time the class action lawsuit commenced, Navan's stock had traded as low as $9.20 per share, representing a nearly 63% decline from the IPO price of $25.00 [5].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. due to the company's failure to meet market expectations in its recent financial results [1][3][4] Group 1: Investigation Details - The investigation focuses on whether Fennec Pharmaceuticals' executive officers may have violated federal securities laws, leading to investor losses [1][4] - Fennec Pharmaceuticals reported financial results for the fiscal year ended December 31, 2025, which included missing both projected revenue and earnings targets [3] Group 2: Investor Information - Investors who purchased Fennec Pharmaceuticals securities and suffered losses are encouraged to join the investigation, with no cost or obligation [2] - Contact information for inquiries includes Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 [2]